Soligenix, Inc. announced that it has extended its development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen. This specific agreement will build upon process development work conducted to date in support of manufacturing scale-up that will eventually be performed in accordance with current good manufacturing practices (cGMPs) at Emergent's manufacturing facility located in Baltimore, MD. Soligenix has been developing RiVax, in conjunction with its heat stabilization technology, ThermoVax®, as a heat-stable biodefense vaccine.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.19 USD | +4.81% |
|
-3.10% | -40.65% |
12/07 | Top Premarket Decliners | MT |
10/07 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday; Traders Await Powell's Second Day of Testimony | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.65% | 6.77M | |
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Soligenix Announces Extension of Development Agreement with Emergent BioSolutions